 We believe that Innoviva stock, a pharmaceuticals royalty management company, is a good buying opportunity at the present time. INVA stock trades near 12 currently and it is, in fact, down 17 from its pre-Covid high of 15 in February 2020 just before the coronavirus pandemic hit the world. 